Another seat -- this time, at Celgene -- another long freight-train of stock grants, retirement benefits and paychecks. So it goes. And again, I wonder about her vast-payout, all supposedly to secure the non-compete -- afterall, Celgene works in the fields of oncology, and inflammatory diseases -- just like New Merck:
. . . .Celgene Corp. announced the election of Carrie Cox to Board. Cox is a member of the Board of Texas Instruments and served on their audit and compensation committees, as well as recently being appointed to the Board of Directors of Cardinal Health. . . .
Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. . . .